Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Cue Biopharma, Inc. (NASDAQ:CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics ...
Stifel analyst Stephen Willey maintains Cue Biopharma (NASDAQ:CUE) with a Buy and lowers the price target from $8 to $4.
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.24) ...
JMP Securities analyst Reni Benjamin maintains Cue Biopharma (NASDAQ:CUE) with a Market Outperform and lowers the price targ...
Piper Sandler analyst Edward Tenthoff maintains Cue Biopharma (NASDAQ:CUE) with a Overweight and lowers the price target fro...
Prioritizing autoimmune programs aims to focus upon near-term and intermediate value creation potential, while retaining oncolo...
Overall response rate (ORR) of 46% and 12-month overall survival (OS) of 96% in first line (1L) recurrent/metastatic (R/M) HPV+...
Cue Biopharma (NASDAQ:CUE) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.28) ...
